99% Purity CAS 1110813-31-4 Dacomitinib Pharmaceutical Dacomitinib API Dacomitinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Model NO.: D-Sung Dacomitinib
• Product Name: Dacomitinib
• Name: Dacomitinib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC
• CAS No: 1110813-31-4
• Mf: C24h25clfn5o2
• Melting Point: 184-187 Oc
• Density: 1.344
• Boiling Point: 665.7
• Water: 3.4%
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 500kg/Month

Product Description

99% Purity CAS 1110813-31-4 Dacomitinib Pharmaceutical Dacomitinib API Dacomitinib

Product Description

Product Details

Product Name	Dacomitinib
Appearance	White Powder
CAS No	1110813-31-4
MF	C24H25ClFN5O2

Dacomitinib is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types.

Application&Function

Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib. 
Biological activityDacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.

Specification